N
Neurocrine Biosciences, Inc. (NBIX)
NMS – Real Time Price. Currency in USD
155.80
+5.21 (3.46%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
155.80
+5.21 (3.46%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.93 | 2.52 | 10 | |
| Quick ratio | 2.85 | 1.78 | 10 | |
| Debt to Equity | 0.12 | -0.80 | 9.0 | |
| Debt to Assets | 0.08 | 0.73 | 9.0 | |
| Interest coverage | N/A | -13.90 | 10 | |
| Weighted average score | 9.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 1.49B | 1.89B | 2.36B | 2.86B | 3.10B |
| Gross Profit | 1.45B | 1.83B | 2.30B | 2.81B | 3.05B |
| Operating Income | 251M | 395M | 597M | 637M | 799M |
| Net Income | 155M | 250M | 341M | 479M | 669M |
| EBITDA | 266M | 416M | 624M | 667M | 829M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 25.9 | 46.15 | 10 |
| Next quarter | 24 | -0.91 | 5.5 |
| Current year | 28.84 | 60.31 | 10 |
| Next year | 15.76 | 24.46 | 9.5 |
| Weighted average score | 8.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 1.12 | 28.76 | 29.05 | -65.01 | 6.0 |
| Y/Y | 42.25 | 2405.06 | 2287.5 | 152.68 | 10 |
| 3y average | 24.34 | 46.18 | 44.49 | 33.48 | 10 |
| 5y average | 22.55 | 26.59 | 25.04 | 29.22 | 10 |
| Weighted average score | 9.0 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | Wide | 8.0 |
| Intangible assets | Wide | 8.0 |
| Switching costs | Medium | 7.0 |
| Network effect | None | 1.0 |
| Economies of scale | Medium | 6.0 |
| Weighted average score | 6.0 | |
Total debt $406.2M significantly exceeds cash reserves ($266.5M), raising financial stability concerns
Total current assets $2.4B exceed Total current liabilities $831.7M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (-0.8), showcasing prudent financial management
The company has no interest-bearing debt, showcasing excellent financial strength
The company generates positive free cash flow $136.7M, supporting its financial health